Investigational injection for chronic hepatitis B
Part of Infections clinical trials.
This study tests an investigational injection called TVAX-008 for people with chronic hepatitis B. It aims to see if the treatment can help clear the hepatitis B surface antigen, which may lead to a functional cure. The study is for people who have been on antiviral therapy and have well-controlled virus levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had chronic hepatitis B for at least 6 months.
- You are currently taking a single antiviral medication for hepatitis B (like tenofovir or entecavir) and have had an undetectable viral load for at least 28 days.
- You are HBeAg negative, meaning the virus is not actively reproducing.
- Your liver function tests (ALT and AST) are within or slightly above normal range.
- You do not have cirrhosis, liver cancer, or other serious liver conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called TVAX-028, given along with your regular hepatitis B medicine, to see if it is safe and how well it works. It might help you control the virus better or even clear the surface antigen.
This study tests a two-step approach for chronic hepatitis B: first a shot called AHB-137, followed by another shot called TVAX-008. The goal is to see if this combination can help control the virus better.
This trial tests an investigational drug called IB-001 to see how well it works and how safe it is. It is for healthy volunteers and people with chronic hepatitis B. The goal is to find the best dose and understand side effects.
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
Hear when a new Chronic hepatitisB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.